VARIZIG

This brand name is authorized in Canada, Estonia, United States

Active ingredients

The drug VARIZIG contains one active pharmaceutical ingredient (API):

1 Human varicela zoster immunoglobulin UNII 33T61IWL27 - HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN

Human varicella zoster immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against varicella-zoster virus. It is used for prophylaxis against varicella zoster virus (VZV) infection. Read about Human varicela zoster immunoglobulin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VARIZIG Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BB03	Varicella/zoster immunoglobulin	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02442183
Country: EE	Ravimiamet	Identifier(s): 1706420
Country: US	FDA, National Drug Code	Identifier(s): 53270-0126, 70257-126, 70504-0126